CME
Emerging Evidence in Second-Line and Potential Considerations in First-Line aGC and GEJ cancers
November 21, 2022
Host: Yelena Janjigian, MD Guest: Sam Klempner, MD HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!